A carregar...
The evolving role of Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia
Ibrutinib, the first in class of the oral covalent Bruton tyrosine kinase (BTK) inhibitors, has profoundly changed the treatment landscape of chronic lymphocytic leukemia (CLL). The phase III RESONATE and RESONATE-2 trials first demonstrated the superiority of ibrutinib over ofatumumab in the relaps...
Na minha lista:
| Publicado no: | Ther Adv Hematol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7970705/ https://ncbi.nlm.nih.gov/pubmed/33796237 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620721989588 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|